NCT02081755 - Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer | Biotech Hunter

Enrollment

336

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG

Everolimus

Everolimus Dosing: 1.5 mg BID (3.0 mg/day) for 12 months

DRUG

Tacrolimus

Tacrolimus Dosing: 0.05 mg/kg BID for 12 months

DRUG

Myfortic

Myfortic®: 360 mg to 1080 mg BID for 12 months

DRUG

CellCept

CellCept: 500 mg to 1500 mg BID for 12 months

DRUG

Imuran

0.5 mg/kg to 2 mg/kg QD for 12 months

Trial Locations (9)

Mount Sinai Medical Center, New York

University of Pennsylvania, Philadelphia

University of Tennessee- Methodist University Hospital, Memphis

Mayo Clinic, Rochester

Northwestern University School of Medicine, Chicago

Washington University School of Medicine, St Louis

University of Kansas Medical Center, Kansas City

Baylor University Medical Center, Dallas

University of California at San Francisco, San Francisco